GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Anti-Microbial Savior BioteQ Co 6864.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

37.50

+10.46%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Anti-Microbial Savior BioteQ Co

Its shares trade on Taipei Exchange under the ticker 6864.TWO. It has been listed since 29 December 2021. In the fiscal year to 31 December 2025, it reported revenue of TWD 706,000 and a net loss of TWD 93.6m. At that date it held total assets of TWD 520.4m and shareholders' equity of TWD 510.5m.

Anti-Microbial Savior BioteQ Co., Ltd. engages in the research and development of drugs. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2021-12-29. The Company’s main products include MEDIACE (new medical dressing), which absorbs wound exudate to maintain the wound in a moist environment, promotes wound healing, and releases antibacterial ingredients to prevent wound infection; FORMOSA-1117 (antibacterial drug), which has antibacterial effects on Gram-positive bacteria and multi-drug resistant bacteria; YUAN-03 (antiviral drug) , which has antiviral effects against human coronavirus hCoV-OC43 and SARS-CoV-2.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
29 Dec 2021

Leadership

Pay as last reported

  • Mr. George TsaiChairman of the Board, General Manager, since 2018
  • Mr. Zhida WeiChief Executive Officer, Vice Chairman of the Board, since 2018
  • Yiwei ZhangDeputy General Manager
  • Ms. Liyu XuHead of Finance
  • Meiling LiaoDirector
  • Liqiu ZhangDirector
  • Mr. Wenzheng ZhangDirector
  • Mr. Jenn-Wen HuangIndependent Director
  • Mr. Fukun LinIndependent Director
  • Yishan LiuIndependent Director
  • Mr. Chih-Hua TsengIndependent Director
  • Mr. Fuchun ZhuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • MEDIACE medical dressing absorbs wound exudate for moist wound healing environment.
  • FORMOSA-1117 targets Gram-positive bacteria and multi-drug resistant bacteria effectively.
  • YUAN-03 antiviral drug shows efficacy against SARS-CoV-2 and hCoV-OC43 viruses.

Weaknesses

  • Kaohsiung city headquarters location may limit access to global markets.
  • Biotechnology sector faces high R&D costs and regulatory hurdles.
  • Health Care sector requires continuous innovation to stay competitive.

Opportunities

  • Expansion into Asian markets for MEDIACE and FORMOSA-1117 products.
  • Growing demand for antiviral drugs like YUAN-03 in global health crises.
  • Increased investment in Biotechnology sector in Taiwan.

Threats

  • Intense competition in the Health Care industry from established firms.
  • Regulatory changes could impact Biotechnology product approvals.
  • Economic downturns may reduce healthcare spending on new drugs.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.